Inmune Bio (INMB) Non-Current Debt (2021 - 2024)
Inmune Bio (INMB) posted Non-Current Debt of $15.0 million for Q4 2024, up 500.0% sequentially from $2.5 million in Q3 2024.
Inmune Bio (INMB) Non-Current Debt (2021 - 2024) Analysis & Trends
Inmune Bio has reported Non-Current Debt for 4 years, with the latest figure at $15.0 million in Q4 2024.
- Quarterly Non-Current Debt changed N/A year-over-year to $15.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $15.0 million (changed N/A YoY) and the FY2024 annual result came in at $15.0 million, changed N/A from the prior year.
- Non-Current Debt climbed to $15.0 million in Q4 2024 per INMB's latest filing, from $2.5 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $15.0 million in Q4 2024 and troughed at $2.4 million in Q3 2023.
- A 4-year average of $9.9 million and a median of $10.9 million in 2022 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2023 and 2024: Non-Current Debt tumbled 80.41% in 2023, then climbed 5.22% in 2024.
- Over 4 years, Non-Current Debt stood at $14.5 million in 2021, then tumbled by 32.93% to $9.7 million in 2022, then tumbled by 75.5% to $2.4 million in 2023, then jumped by 531.31% to $15.0 million in 2024.
- According to Business Quant data, Non-Current Debt over the past three periods registered $15.0 million, $2.5 million, and $5.0 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 8.96 Bn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 15.00 Mn |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2024 | 7.50 Mn |
| Sep 30, 2023 | 2.38 Mn |
| Jun 30, 2023 | 4.82 Mn |
| Mar 31, 2023 | 7.26 Mn |
| Dec 31, 2022 | 9.70 Mn |
| Sep 30, 2022 | 12.13 Mn |
| Jun 30, 2022 | 14.57 Mn |
| Mar 31, 2022 | 14.51 Mn |
| Dec 31, 2021 | 14.46 Mn |
| Sep 30, 2021 | 14.40 Mn |
| Jun 30, 2021 | 14.35 Mn |